These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens]. Smirnova LB; Sokolova VI Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102 [TBL] [Abstract][Full Text] [Related]
3. [Ciprofloxacin--a highly effective drug from the fluoroquinolone group]. Iakovlev VP Antibiot Khimioter; 1997; 42(6):4-14. PubMed ID: 9313059 [No Abstract] [Full Text] [Related]
4. Comparative assessment of the pharmacokinetics and pharmacodynamics of ciprofloxacin after single i.v. doses of 200 and 400mg. Garraffo R; Drugeon HB Drugs; 1995; 49 Suppl 2():317-20. PubMed ID: 8549347 [No Abstract] [Full Text] [Related]
5. In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex. Alovero FL; Olivera ME; Manzo RH Int J Antimicrob Agents; 2003 May; 21(5):446-51. PubMed ID: 12727078 [TBL] [Abstract][Full Text] [Related]
6. Penetration of topical ciprofloxacin into the aqueous. Ghazi-Nouri SM J Cataract Refract Surg; 2003 Nov; 29(11):2043-4; author reply 2043-4. PubMed ID: 14670403 [No Abstract] [Full Text] [Related]
7. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Dalhoff A Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301 [No Abstract] [Full Text] [Related]
8. Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis. Mikamo H; Ninomiya M; Tamaya T J Infect Chemother; 2003 Sep; 9(3):276-7. PubMed ID: 14513401 [TBL] [Abstract][Full Text] [Related]
9. Penetration of ciprofloxacin into the mucosa of the human maxillary sinus. Maier H; Zielinski D; Seigoleit A J Chemother; 1989 Jul; 1(4 Suppl):570-1. PubMed ID: 16312536 [No Abstract] [Full Text] [Related]
11. In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections. Speciale A; Blandino G; Caccamo F; Serra A Drugs; 1995; 49 Suppl 2():403-5. PubMed ID: 8549378 [No Abstract] [Full Text] [Related]
12. Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin. Jeffres MN; Shuster JE; Barclay SM Ann Pharmacother; 2011 Jun; 45(6):824-5. PubMed ID: 21666093 [No Abstract] [Full Text] [Related]
13. Inadvertent use of ciprofloxacin as a single agent in undiagnosed tuberculosis. Khilnani G; Gupta RC J Assoc Physicians India; 1998 Apr; 46(4):401. PubMed ID: 11273333 [No Abstract] [Full Text] [Related]
14. The rapid development of fluoroquinolone resistance in M. tuberculosis. Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180 [No Abstract] [Full Text] [Related]
15. Fluoroquinolone resistance trends and animal drug use: a retrospective analysis. Radostits OM Int J Infect Dis; 2004 May; 8(3):187-9; author reply 190-2. PubMed ID: 15109595 [No Abstract] [Full Text] [Related]
16. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified? Murphy M; Brown AE; Sepkowitz KA; Bernard EM; Kiehn TE; Armstrong D Clin Infect Dis; 1997 Aug; 25(2):346-8. PubMed ID: 9332551 [No Abstract] [Full Text] [Related]
17. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R; Markham A; Balfour JA Drugs; 1996 Jun; 51(6):1019-74. PubMed ID: 8736621 [TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. Sánchez-Recio MM; Colino CI; Sánchez-Navarro A J Antimicrob Chemother; 2000 Mar; 45(3):321-8. PubMed ID: 10702551 [TBL] [Abstract][Full Text] [Related]